Business
Century Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update
Preclinical pipeline re-prioritization to focus on four potentially transformative programs to advance toward clinic, led by CNTY-308 in B-cell mediated autoimmune diseases and malignancies New concentrated clinical focus for CNTY-101 based on unique profile with transformational potential in autoimmune disease; data anticipated in 2025 Cash runway estimate extended into fourth quarter of 2026 PHILADELPHIA, March 19, 2025 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC),
About this update from Century Therapeutics, Inc.
[{"type":"image","alt":"Century Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Century Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":89,"url":"https://media.zenfs.com/en/globenewswire.com/1dafc8564c4cf69fd2fbdeedd53053be"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/1qMMhZqDcCAAdTlry0aLDQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEyNTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/1dafc8564c4cf69fd2fbdeedd53053be","width":300,"height":89}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Preclinical pipeline re-prioritization to focus on four potentially transformative programs to advance toward clinic, led by CNTY-308 in B-cell mediated autoimmune diseases and malignancies","length":189,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":189,"olType":false},{"type":"list","items":[{"val":[{"type":"text","content":"New concentrated clinical focus for CNTY-101 based on unique profile with transformational potential in autoimmune disease; data anticipated in 2025","length":148,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":148,"olType":false},{"type":"list","items":[{"val":[{"type":"text","content":"Cash runway estimate extended into fourth quarter of 2026","length":57,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":57,"olType":false},{"type":"text","content":"PHILADELPHIA, March 19, 2025 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in autoimmune disease and cancer, today reported financial results and business highlights for the full year 2024.","length":324,"tagName":"p"},{"type":"text","content":"“Today we announced a pipeline re-prioritization to streamline resources on advancing candidates that are potentially transformational or best-in-class in diseases with high unmet need. We ended the year with a strong cash position, which we will leverage to achieve meaningful milestones and drive value for all stakeholders as we take the company forward in a new direction,” said Brent Pfeiffenberger, Pharm.D., Chief Executive Officer of Century Therapeutics. “We have made the strategic decision to discontinue the Phase 1 ELiPSE-1 trial early, and we thank the patients, providers and ...